Enzastaurin and pemetrexed in non-small cell lung cancer
Author Information
Author(s): Tekle C, Giovannetti E, Sigmond J, Graff J R, Smid K, Peters G J
Primary Institution: VU University Medical Center, Amsterdam, The Netherlands
Hypothesis
This study aimed to investigate the main pharmacological aspects of the enzastaurin-pemetrexed combination in NSCLC cells.
Conclusion
The combination of enzastaurin and pemetrexed was found to be highly synergistic and significantly increased apoptosis in non-small cell lung cancer cells.
Supporting Evidence
- The combination of enzastaurin and pemetrexed significantly increased apoptosis in NSCLC cells.
- Enzastaurin reduced the expression of thymidylate synthase, which is important for pemetrexed activity.
- The study demonstrated that the drug combination had a strong synergistic effect on cell growth inhibition.
Takeaway
Researchers found that combining two cancer drugs, enzastaurin and pemetrexed, works better together than alone to help kill cancer cells.
Methodology
The study used pharmacologic interaction analysis, flow cytometry, ELISAs, reverse transcription–PCR, and western blot to assess the effects of the drug combination on cancer cells.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website